BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Dec 14, 2009
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 12/11 cls
UBS Derik de Bruin Price target Neutral 13% $5.55
de Bruin lowered his target to $5.50 from $9.50 based on a cautious outlook on the demand for microarrays for genome-wide association studies. He thinks the "pause" in arrays sales for such studies will likely persist until at least 2H10.
Genzyme Corp. (NASDAQ:GENZ) Summer Street Jon Stephenson Downgrade Sell (from neutral) 0% $49.74
Stephenson also lowered his target to $41 from $52-$53. He believes there is...

Read the full 662 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >